The country can be provided with pharmaceuticals, cheaper than foreign analogues, however there are problems with patents.
Ukrainian pharmaceutical manufacturers are capable of providing the country with qualitative pharmaceuticals, cheaper than foreign analogues. This can be bolstered, in particular, by the settlement of intellectual property patent, the validity term of which is unreasonably extended, Representative of Yuria-Pharm Andrei Krivoruchko told.
“Each invention patent is valid 20 years since the submission of the application. After that, if the subject of invention is the pharmaceutical and it requires obtaining special permission – in this case from the Ministry of Healthcare of Ukraine, - then the validity can be extended for other 5 years”, Krivoruchko noted.
He states that in many cases the patents, issued in 1990s, are not valid, because when they were obtained, the necessary requirements, in particular, the novelty of invention, were not fulfilled in Ukraine.
According to him, many court proceedings are being conducted in regard to particularly national manufacturer, which supposedly violates the intellectual property law of foreign companies.
In particular, currently Yuria-Pharm adjudicates its right to the presence on the Ukrainian market with its antibiotic, which costs twice cheaper than the foreign.
As it is reported, the company developed its pharmaceutical, but it was banned to be sold based on the fact that it violates the patent right of other business entity. The foreign company filed a claim on suspension of violation of the rights of the patent owner.
“National producers are involved in the judicial proceedings, which are the result of illegal activities, including intellectual property service”, the expert considers.
According to Krivoruchko, Yuria-Pharm is not going to stop on protection of its economic interests and interests of Ukrainian consumer. On August 16, the next meeting is appointed in the Appellate Court. If its decision turns out to be unacceptable, then the company is ready to go to the High Economic Court, and the European Court of Human Rights.
Source: Correspondent.
